Results 171 to 180 of about 183,209 (216)

Histone Deacetylase 3 [PDF]

, 2020
openaire   +1 more source

Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies. [PDF]

World J Clin Oncol
Xiao S, Xu XZ, Liao M, Song DD, Tang JF, Zhou CF.   +5 more
europepmc   +1 more source

Histone Deacetylase 4 [PDF]

, 2020
openaire   +1 more source

Histone deacetylase 6: A new player in oxidative stress‑associated disorders and cancers (Review). [PDF]

Int J Mol Med
Qu F, Zhao Q, Jin Y.
europepmc   +1 more source

Histone deacetylase (HDAC) [PDF]

Science-Business eXchange, 2010
openaire   +1 more source

Regulation of PD-L1 Expression by SAHA-Mediated Histone Deacetylase Inhibition in Lung Cancer Cells. [PDF]

Cancers (Basel)
Natarajan U, Rathinavelu A.
europepmc   +1 more source

Correction: Histone deacetylase inhibitors inhibit lung adenocarcinoma metastasis via HDAC2/YY1 mediated downregulation of Cdh1. [PDF]

Sci Rep
Wang D, Yang Y, Cao Y, Meng M, Wang X, Zhang Z, Fu W, Duan S, Tang L.   +8 more
europepmc   +1 more source

High-throughput screening identifies the activity of histone deacetylase inhibitors in patient-derived models of soft tissue sarcoma. [PDF]

Cancer Biol Ther
Danks MR, Manasterski PJ, Beetham H, Dawson JC, Elliott RJR, Culley J, Krishna R, Muir M, Thomson JP, Oswald AJ, Ewing A, Kerrison WGJ, Huang PH, Nixon I, Carragher NO, Brunton VG.   +15 more
europepmc   +1 more source

Off-target binding of the histone deacetylase inhibitor vorinostat to carbonic anhydrase II and IX. [PDF]

Acta Crystallogr F Struct Biol Commun
Gulkis MC, Hodgkinson JT, Sele CP, Knecht W, McKenna R, Fisher SZ.   +5 more
europepmc   +1 more source

Antiplasmodial activity of pentyloxyamide-based histone deacetylase inhibitors against Plasmodium falciparum parasites. [PDF]

Int J Parasitol Drugs Drug Resist
Dawood WA, Fisher GM, Kremeyer J, Fischer F, Home JL, Goodman CD, Lam KS, Maier AG, Kurz T, Andrews KT.   +9 more
europepmc   +1 more source